Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Retained Earnings (2016 - 2025)

Dexcom (DXCM) has disclosed Retained Earnings for 16 consecutive years, with $115.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 92.8% to $115.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $115.0 million, a 92.8% decrease, with the full-year FY2025 number at $115.0 million, down 92.8% from a year prior.
  • Retained Earnings was $115.0 million for Q4 2025 at Dexcom, down from $2.2 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $2.2 billion in Q3 2025 to a low of -$161.8 million in Q1 2021.
  • A 5-year average of $420.0 million and a median of $33.1 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 1100.0% in 2021, then skyrocketed 8763.93% in 2023.
  • Dexcom's Retained Earnings stood at $138.7 million in 2021, then skyrocketed by 246.0% to $479.9 million in 2022, then skyrocketed by 112.84% to $1.0 billion in 2023, then soared by 56.41% to $1.6 billion in 2024, then tumbled by 92.8% to $115.0 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Retained Earnings are $115.0 million (Q4 2025), $2.2 billion (Q3 2025), and $1.9 billion (Q2 2025).